医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Chinese expert consensus on refined diagnosis,treatment,and management of advanced primary liver cancer(2023 edition)

摘要Hepatocellular carcinoma(HCC),commonly known as primary liver cancer,is a major cause of malignant tumors and cancer-related deaths in China,accounting for approximately 85%of all cancer cases in the country.Several guidelines have been used to diagnose and treat liver cancer.However,these guidelines provide a broad definition for classifying advanced liver cancer,with an emphasis on a singular approach,without considering treatment options for individual patients.Therefore,it is necessary to establish a comprehensive and practical expert consensus,specifically for China,to enhance the diagnosis and treatment of HCC using the Delphi method.The classification criteria were refined for Chinese patients with HCC,and the corresponding optimal treatment regimen recommendations were developed.These recommendations took into account various factors,including tumor characteristics,vascular tumor thrombus grade,distant metastasis,liver function status,portal hypertension,and the hepatitis B virus replication status of patients with primary HCC,along with treatment prognosis.The findings and rec-ommendations provide detailed,scientific,and reasonable individualized diagnosis and treatment strategies for clinicians.

更多
广告
作者 Xiufeng Liu [1] Feng Xia [2] Yue Chen [3] Huichuan Sun [4] Zhengqiang Yang [5] Bo Chen [6] Ming Zhao [7] Xinyu Bi [8] Tao Peng [9] Aizier Ainiwaer [3] Zhiwen Luo [8] Fusheng Wang [10] Yinying Lu [11] National Clinical Research Center for Infectious Diseases Society of Hepatology,Beijing Medical Association Translational Medicine Branch,China Association of Gerontology and Geriatrics 学术成果认领
作者单位 Department of Medical Oncology,Bayi Hospital Affiliated to Nanjing Chinese Medical University Nanjing,Jiangsu,China [1] Department of Hepatobiliary Surgery,Southwest Hospital,Army Medical University Chongqing,China [2] Senior Department of Hepatology,The Fifth Medical Center of PLA General Hospital,Beijing,China [3] Department of Liver Surgery and Transplantation,Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai,China [4] Department of Interventional Therapy,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China [5] Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China [6] Department of Minimally Invasive Interventional Therapy,Liver Cancer Study and Service Group,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China [7] Department of Hepatobiliary Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China [8] Department of Hepatobiliary Surgery,The First Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi,China [9] Senior Department of Infectious Diseases,The Fifth Medical Center of PLA General Hospital,Beijing,China [10] Comprehensive Liver Cancer Center,The Fifth Medical Center of PLA General Hospital,Beijing,China [11]
栏目名称
DOI 10.1016/j.livres.2024.05.001
发布时间 2024-07-16(万方平台首次上网日期,不代表论文的发表时间)
提交
  • 浏览16
  • 下载2
肝脏研究(英文)

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷